VVOS vs. ZYXI, CTSO, NSPR, SURG, EDAP, HYPR, ICCM, CTCX, MDAI, and APT
Should you be buying Vivos Therapeutics stock or one of its competitors? The main competitors of Vivos Therapeutics include Zynex (ZYXI), Cytosorbents (CTSO), InspireMD (NSPR), SurgePays (SURG), EDAP TMS (EDAP), Hyperfine (HYPR), IceCure Medical (ICCM), Carmell (CTCX), Spectral AI (MDAI), and Alpha Pro Tech (APT). These companies are all part of the "medical equipment" industry.
Vivos Therapeutics vs. Its Competitors
Zynex (NASDAQ:ZYXI) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.
Zynex has a net margin of -4.30% compared to Vivos Therapeutics' net margin of -76.82%. Zynex's return on equity of -23.70% beat Vivos Therapeutics' return on equity.
29.7% of Zynex shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 49.3% of Zynex shares are held by company insiders. Comparatively, 3.0% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Zynex has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.01, indicating that its share price is 601% more volatile than the S&P 500.
Zynex has higher revenue and earnings than Vivos Therapeutics. Zynex is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Zynex had 4 more articles in the media than Vivos Therapeutics. MarketBeat recorded 9 mentions for Zynex and 5 mentions for Vivos Therapeutics. Vivos Therapeutics' average media sentiment score of 0.85 beat Zynex's score of 0.09 indicating that Vivos Therapeutics is being referred to more favorably in the news media.
Zynex currently has a consensus price target of $6.00, indicating a potential upside of 155.32%. Vivos Therapeutics has a consensus price target of $4.82, indicating a potential upside of 13.87%. Given Zynex's higher possible upside, equities analysts plainly believe Zynex is more favorable than Vivos Therapeutics.
Summary
Zynex beats Vivos Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Vivos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vivos Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VVOS) was last updated on 7/4/2025 by MarketBeat.com Staff
